Increasing the use of arteriovenous fistula in hemodialysis: Economic benefits and economic barriers

Donald Schon, Steven W. Blume, Kimberly Niebauer, Christopher S. Hollenbeak, Gregory de Lissovoy

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

The Fistula First Initiative set a goal of 66% arteriovenous (AV) fistula-based access among US hemodialysis patients. This study modeled the impact of achieving the target AV fistula placement rate on Medicare expenditures and on dialysis patient survival and also reviewed economic disincentives for providers that will inhibit achieving this target. The model projects lifetime costs and survival in the US 2003 incident hemodialysis population. Annual treatment costs were estimated from previous analyses of Medicare expenditures by access modality. Patient survival by mode of access was derived from the Dialysis Morbidity and Mortality Study (DMMS). These parameters were applied to a cohort of patients who meet the 66% AV fistula target and an identical cohort with the current vascular access case mix. Comparison of outcomes yields estimates of differential total expenditures and total patient life-years. If prevalence AV fistula-based access in the 2003 incident hemodialysis cohort were 66% rather than the observed 35%, then the Center for Medicare and Medicaid Services would save $840 million in access-attributed expenditures over the expected lifetime of these patients. However, population survival would increase by 35,000 additional life-years, increasing total lifetime expenditures by a net of $1.4 billion. Relative to the current mix of access modality, the shift to 66% AV fistula would be achieved at a net incremental cost of $40,000 per year of life gained. Economic barriers to reaching this goal include financial disincentives to providing adequate predialysis care, performing AV fistula surgical procedures, and monitoring vascular access flow. Achievement of the 66% AV fistula target is cost-effective. Financial incentives in the form of higher reimbursement to encourage wider use of AV fistula placement also could be cost-effective.

Original languageEnglish (US)
Pages (from-to)268-276
Number of pages9
JournalClinical Journal of the American Society of Nephrology
Volume2
Issue number2
DOIs
StatePublished - Mar 1 2007

Fingerprint

Arteriovenous Fistula
Renal Dialysis
Economics
Health Expenditures
Motivation
Costs and Cost Analysis
Survival
Medicare
Dialysis
Vascular Surgical Procedures
Centers for Medicare and Medicaid Services (U.S.)
Diagnosis-Related Groups
Health Care Costs
Population
Fistula
Blood Vessels
Morbidity
Mortality

All Science Journal Classification (ASJC) codes

  • Epidemiology
  • Critical Care and Intensive Care Medicine
  • Nephrology
  • Transplantation

Cite this

@article{a5885a456c7b4b228c6a1161e6e4dfd9,
title = "Increasing the use of arteriovenous fistula in hemodialysis: Economic benefits and economic barriers",
abstract = "The Fistula First Initiative set a goal of 66{\%} arteriovenous (AV) fistula-based access among US hemodialysis patients. This study modeled the impact of achieving the target AV fistula placement rate on Medicare expenditures and on dialysis patient survival and also reviewed economic disincentives for providers that will inhibit achieving this target. The model projects lifetime costs and survival in the US 2003 incident hemodialysis population. Annual treatment costs were estimated from previous analyses of Medicare expenditures by access modality. Patient survival by mode of access was derived from the Dialysis Morbidity and Mortality Study (DMMS). These parameters were applied to a cohort of patients who meet the 66{\%} AV fistula target and an identical cohort with the current vascular access case mix. Comparison of outcomes yields estimates of differential total expenditures and total patient life-years. If prevalence AV fistula-based access in the 2003 incident hemodialysis cohort were 66{\%} rather than the observed 35{\%}, then the Center for Medicare and Medicaid Services would save $840 million in access-attributed expenditures over the expected lifetime of these patients. However, population survival would increase by 35,000 additional life-years, increasing total lifetime expenditures by a net of $1.4 billion. Relative to the current mix of access modality, the shift to 66{\%} AV fistula would be achieved at a net incremental cost of $40,000 per year of life gained. Economic barriers to reaching this goal include financial disincentives to providing adequate predialysis care, performing AV fistula surgical procedures, and monitoring vascular access flow. Achievement of the 66{\%} AV fistula target is cost-effective. Financial incentives in the form of higher reimbursement to encourage wider use of AV fistula placement also could be cost-effective.",
author = "Donald Schon and Blume, {Steven W.} and Kimberly Niebauer and Hollenbeak, {Christopher S.} and {de Lissovoy}, Gregory",
year = "2007",
month = "3",
day = "1",
doi = "10.2215/CJN.01880606",
language = "English (US)",
volume = "2",
pages = "268--276",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "2",

}

Increasing the use of arteriovenous fistula in hemodialysis : Economic benefits and economic barriers. / Schon, Donald; Blume, Steven W.; Niebauer, Kimberly; Hollenbeak, Christopher S.; de Lissovoy, Gregory.

In: Clinical Journal of the American Society of Nephrology, Vol. 2, No. 2, 01.03.2007, p. 268-276.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Increasing the use of arteriovenous fistula in hemodialysis

T2 - Economic benefits and economic barriers

AU - Schon, Donald

AU - Blume, Steven W.

AU - Niebauer, Kimberly

AU - Hollenbeak, Christopher S.

AU - de Lissovoy, Gregory

PY - 2007/3/1

Y1 - 2007/3/1

N2 - The Fistula First Initiative set a goal of 66% arteriovenous (AV) fistula-based access among US hemodialysis patients. This study modeled the impact of achieving the target AV fistula placement rate on Medicare expenditures and on dialysis patient survival and also reviewed economic disincentives for providers that will inhibit achieving this target. The model projects lifetime costs and survival in the US 2003 incident hemodialysis population. Annual treatment costs were estimated from previous analyses of Medicare expenditures by access modality. Patient survival by mode of access was derived from the Dialysis Morbidity and Mortality Study (DMMS). These parameters were applied to a cohort of patients who meet the 66% AV fistula target and an identical cohort with the current vascular access case mix. Comparison of outcomes yields estimates of differential total expenditures and total patient life-years. If prevalence AV fistula-based access in the 2003 incident hemodialysis cohort were 66% rather than the observed 35%, then the Center for Medicare and Medicaid Services would save $840 million in access-attributed expenditures over the expected lifetime of these patients. However, population survival would increase by 35,000 additional life-years, increasing total lifetime expenditures by a net of $1.4 billion. Relative to the current mix of access modality, the shift to 66% AV fistula would be achieved at a net incremental cost of $40,000 per year of life gained. Economic barriers to reaching this goal include financial disincentives to providing adequate predialysis care, performing AV fistula surgical procedures, and monitoring vascular access flow. Achievement of the 66% AV fistula target is cost-effective. Financial incentives in the form of higher reimbursement to encourage wider use of AV fistula placement also could be cost-effective.

AB - The Fistula First Initiative set a goal of 66% arteriovenous (AV) fistula-based access among US hemodialysis patients. This study modeled the impact of achieving the target AV fistula placement rate on Medicare expenditures and on dialysis patient survival and also reviewed economic disincentives for providers that will inhibit achieving this target. The model projects lifetime costs and survival in the US 2003 incident hemodialysis population. Annual treatment costs were estimated from previous analyses of Medicare expenditures by access modality. Patient survival by mode of access was derived from the Dialysis Morbidity and Mortality Study (DMMS). These parameters were applied to a cohort of patients who meet the 66% AV fistula target and an identical cohort with the current vascular access case mix. Comparison of outcomes yields estimates of differential total expenditures and total patient life-years. If prevalence AV fistula-based access in the 2003 incident hemodialysis cohort were 66% rather than the observed 35%, then the Center for Medicare and Medicaid Services would save $840 million in access-attributed expenditures over the expected lifetime of these patients. However, population survival would increase by 35,000 additional life-years, increasing total lifetime expenditures by a net of $1.4 billion. Relative to the current mix of access modality, the shift to 66% AV fistula would be achieved at a net incremental cost of $40,000 per year of life gained. Economic barriers to reaching this goal include financial disincentives to providing adequate predialysis care, performing AV fistula surgical procedures, and monitoring vascular access flow. Achievement of the 66% AV fistula target is cost-effective. Financial incentives in the form of higher reimbursement to encourage wider use of AV fistula placement also could be cost-effective.

UR - http://www.scopus.com/inward/record.url?scp=34548854812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548854812&partnerID=8YFLogxK

U2 - 10.2215/CJN.01880606

DO - 10.2215/CJN.01880606

M3 - Article

C2 - 17699424

AN - SCOPUS:34548854812

VL - 2

SP - 268

EP - 276

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 2

ER -